Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.
SEC Form 4 Filing
Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a portion of its holdings in multiple transactions on January 11, 2024.
Summary
- Lilly Endowment Inc. sold a total of 11,544 shares of Eli Lilly & Co. common stock on January 11, 2024.
- The sales were executed in multiple transactions throughout the day at varying weighted average prices.
- The prices ranged from $630.244 to $639.13 per share.
- Following these transactions, Lilly Endowment Inc. still holds a substantial 99,543,810 shares of Eli Lilly & Co. common stock.
- The sales were conducted under a pre-arranged trading plan.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a share sale, which is neither positive nor negative in itself. It reflects normal market activity.
Industry Context
Form 4 filings are a routine part of regulatory compliance for significant shareholders and insiders, providing transparency into their trading activities. This filing indicates a planned sale of shares by a major shareholder, which is not uncommon.
Comparison to Industry Standards
- Form 4 filings are standard practice for reporting insider transactions in publicly traded companies, as mandated by the SEC.
- The level of detail provided in this Form 4, including weighted average prices and ranges, is consistent with regulatory requirements.
- Similar filings are made by insiders of other pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ) when they trade their company's stock.
Stakeholder Impact
- The share sale by Lilly Endowment Inc. may have a minor impact on the stock price of Eli Lilly & Co., but is unlikely to be significant given the relatively small volume of shares sold compared to the total outstanding shares.
- The sale does not appear to have any direct impact on employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 01/11/2024 | Date of the share sale transactions. |
| 01/12/2024 | Date the Form 4 was signed. |
Keywords
Eli Lilly & Co, Lilly Endowment Inc, share sale, insider trading, stock transaction, Form 4, equity securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.